RxDoctor Payments DataLook up a doctor →

Mircea Badara, MD

Pulmonary Disease · New Britain, CTNPI 1801877865

Payments from drug & device makers

$1,003,009in general payments, 2019–2025

Across 773 payments — averaging $1297.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$744K
  • AstraZeneca$228K
  • CSL Behring$21K
  • GSK$3K
  • Mallinckrodt Hospital Products Inc.$900
  • Regeneron Healthcare Solutions, Inc.$686
  • plus $6K from 39 others

What the payments were for

  • Food & beverage$13,09196%
  • Education$5154%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,003,009 in reported general payments places this provider in the 95th percentile of 255 pulmonary disease providers in Connecticut.

See all pulmonary disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$111,946
Medicare patients
405
Services billed
1,073

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter390$302,889
Breztri AerosphereBudesonide/Glycopyr/Formoterol165$119,153
XolairOmalizumab26$90,279
Stiolto RespimatTiotropium Br/Olodaterol Hcl149$86,223
Fasenra PenBenralizumab12$74,200
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr98$57,562
NucalaMepolizumab12$51,526
SymbicortBudesonide/Formoterol Fumarate154$49,434
Breo ElliptaFluticasone/Vilanterol107$48,264
Spiriva RespimatTiotropium Bromide51$46,236
EliquisApixaban53$31,748
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate135$25,291
SunosiSolriamfetol Hcl13$16,142
Incruse ElliptaUmeclidinium Bromide25$14,089
DuleraMometasone/Formoterol25$13,722

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Nucala, Breo Ellipta, Incruse Ellipta$2,715$483,053657 claims
AstraZenecaBreztri Aerosphere, Symbicort, Pulmicort Flexhaler$227,685$172,916334 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat$613$140,568213 claims
Genentech, Inc.Xolair$743,657$90,27926 claims
PfizerEliquis$109$31,74853 claims
Axsome Therapeutics, Inc.Sunosi$261$16,14213 claims
MerckDulera$51$13,72225 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 255 pulmonary disease providers in Connecticut.

Other pulmonary disease in New Britain

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →